"10.1371_journal.pone.0126815","plos one","2015-05-12T00:00:00Z","Melissa I March; Carl Geahchan; Julia Wenger; Nandini Raghuraman; Anders Berg; Hamish Haddow; Bri Ann Mckeon; Rulx Narcisse; Jean Louis David; Jennifer Scott; Ravi Thadhani; S Ananth Karumanchi; Sarosh Rana","Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America; Division of Maternal Fetal Medicine/Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States of America; Center for Vascular Biology and Research, Beth Israel Deaconess Medical Center Boston, MA, United States of America; Division of Nephrology/Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States of America; Savjani Institute for Health Research, Windham, ME, United States of America; Department of Obstetrics and Gynecology, Hospital Albert Schweitzer, Deshapelles, Haiti; Division of Womens Health/Department of Medicine, Brigham and Womens Hospital, Boston, MA, United States of America; Division of Nephrology/Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, United States of America; Howard Hughes Medical Institute, Boston, MA, United States of America; Maternal Fetal Medicine/Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, United States of America","Conceived and designed the experiments: MM CG NR JS RT SAK SR. Performed the experiments: MM CG NR AB HH BAM RN JLD SR. Analyzed the data: JW RT SAK SR. Contributed reagents/materials/analysis tools: JW AB RT SAK SR. Wrote the paper: MM CG JW NR JS RT SAK SR.","S.A.K. is a co-inventor on patents related to preeclampsia biomarkers and is a consultant to Siemens and has financial interest in Aggamin Therapeutics. R.T. has patents in preeclampsia prediction markers, is a consultant to Roche and has a financial interest in Aggamin Therapeutics. All other authors report no conflicts. S.A.K. is co-inventor on multiple patents (USPTO #7,740,849, #7,407,658, #7,335,362, #7,344,892) related to the use of angiogenic markers for the diagnosis, prediction and therapy of preeclampsia. R.T. is a co-inventor on a patent (USPTO #7,344,892) related to the use of angiogenic proteins for the prediction of preeclampsia. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","05","Melissa I March","MIM",13,TRUE,7,9,4,8,TRUE,FALSE,FALSE,0,NA,FALSE
